Almac collaborates with Alexion for product packaging and distribution of Soliris during German E. Coli outbreak Almac, a leading provider of contract solutions to the global pharmaceutical and biotech industries, responded earlier this complete yr to an urgent demand from their client partner, Alexion Pharmaceuticals, Inc. Coli outbreak in Germany earlier this full year suivre ce site . Coli infection, which led to more than 800 cases of STEC-HUS , an ultra-rare and life-threatening complication of the infection.
The compound is a DNA minor groove binder and is currently in pre-clinical advancement with IND submitting targeted for Q3 2012. CEO Dr Miroslav Ravic stated ‘We were rapidly impressed with the approach taken by Almac plus they have already shown an intuitive knowledge of what it will take to support a small company like ours. We anticipate a continued successful relationship’. Related StoriesTumour DNA in the blood can accurately monitor tumor in actual timeCologuard stool DNA check: An accurate screening option for Alaska Native people who have colorectal cancerCancer DNA in patient's bloodstream may help deliver personalized treatment for liver cancerRick Dyer, VP Functions, Almac further commented ‘Almac has a wealth of experience in early phase clinical development and we are delighted to attempt this phase of function for MGB Biopharma and hope this is the first of many successful tasks between our businesses.’ Pursuing on from their knowledge in early stage and steady growth in late phase clinical development, Almac recently announced a capacity expansion within its API facility, further leveraging its API and Drug Product integrated offering.